- $46.38m
- $47.14m
- $0.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.36 | ||
| Price to Tang. Book | 1.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 283.82 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.54% | ||
| Return on Equity | 0.89% | ||
| Operating Margin | -541.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.38 | 0.26 | 0.28 | 0.23 | 0.16 | n/a | n/a | -17.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +2.59 | -95.16 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. It is also focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. It has several ongoing trials in the areas of heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.
Directors
- Michael Feldschuh CHM (51)
- Robert Michel CFO (64)
- Jonathan Feldschuh CSO (56)
- Henry Cremisi IND (63)
- Caleb Desrosiers IND
- Edward Feuer IND (65)
- Joy Goudie IND (64)
- James Lombard IND (86)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 5th, 1971
- Public Since
- July 25th, 1983
- No. of Employees
- 37
- Sector
- Collective Investments
- Industry
- Financials
- Exchange
NASDAQ Capital Market- Shares in Issue
- 4,806,347
- Address
- SUITE 7120, 350 FIFTH AVENUE, NEW YORK, 10118
- Web
- https://www.daxor.com/
- Phone
- +1 2122440555
- Contact
- Bret Shapiro
- Auditors
- Citrin, Cooperman & Company
Upcoming Events for DXR
Similar to DXR
Moringa Acquisition
NASDAQ Capital Market
Moringa Acquisition
NASDAQ Capital Market
OFS Credit
NASDAQ Capital Market
FAQ
What is the Daxor share price?
As of Today at 19:06 UTC, shares in Daxor are trading at $9.65. This share price information is delayed by 15 minutes.
How has the Daxor share price performed this year?
Shares in Daxor last closed at $9.65 and the price had moved by -13.41% over the past 365 days. In terms of relative price strength the Daxor share price has underperformed the S&P500 Index by -29.21% over the past year.
What are the analyst and broker recommendations for Daxor?
The overall consensus recommendation for Daxor is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Daxor dividend yield?
Daxor does not currently pay a dividend.
Does Daxor pay a dividend?
Daxor does not currently pay a dividend.
When does Daxor next pay dividends?
Daxor does not currently pay a dividend.
How do I buy Daxor shares?
To buy shares in Daxor you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Daxor?
As of the previous close price of $9.65, shares in Daxor had a market capitalisation of $46.38m.
Where are Daxor shares listed?
Here are the trading details for Daxor:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DXR
What kind of share is Daxor?
Based on an overall assessment of its quality, value and momentum Daxor is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Daxor share price forecast for 2024?
The analyst consensus target price for shares in Daxor is $23.25. That is 140.93% above the last closing price of $9.65.
Analysts covering Daxor currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Daxor share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Daxor. Over the past six months, its share price has outperformed the S&P500 Index by +1.08%.
As of the last closing price of $9.65, shares in Daxor were trading +6.89% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Daxor PE Ratio?
The Daxor PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Daxor?
Daxor's management team is headed by:
- Michael Feldschuh - CHM
- Robert Michel - CFO
- Jonathan Feldschuh - CSO
- Henry Cremisi - IND
- Caleb Desrosiers - IND
- Edward Feuer - IND
- Joy Goudie - IND
- James Lombard - IND